IAN MORTIMER - 02 Jan 2026 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
PRESIDENT & CEO, Director
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
02 Jan 2026
Net transactions value
-$1,477,493
Form type
4
Filing time
02 Jan 2026, 18:49:48 UTC
Previous filing
09 Dec 2025
Next filing
09 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MORTIMER IAN PRESIDENT & CEO, Director 3650 GILMORE WAY, BURNABY, BRITISH COLUMBIA, CANADA /s/ Nathaniel Adams, Attorney-in-fact 02 Jan 2026 0001619961

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise $299,600 +40,000 +667% $7.49 46,000 02 Jan 2026 Direct
transaction XENE Common Shares Sale $1,684,447 -37,938 -82% $44.40 8,062 02 Jan 2026 Direct F1, F2
transaction XENE Common Shares Sale $92,646 -2,062 -26% $44.93 6,000 02 Jan 2026 Direct F1, F3
holding XENE Common Shares 14,300 02 Jan 2026 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -40,000 -100% $0.000000 0 02 Jan 2026 Common Shares 40,000 $7.49 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024.
F2 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $43.91 to $44.90, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $44.91 to $45.125, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The shares subject to the option are fully vested and exercisable.